CR

FAIR Applauds House Republicans on Spending Package that Includes Funding and Critical Reforms to End the Biden Border Crisis

Retrieved on: 
Monday, September 18, 2023
Federation for American Immigration Reform, Senate, Democrat, DHS, Nationality and Borders Act 2022, Government, Congress, Federation, CR, United States Secretary of Homeland Security, House, FAIR, Drug

The House-drafted Continuing Resolution (CR) that would fund the federal government beyond September 30 includes nearly all of H.R.

Key Points: 
  • The House-drafted Continuing Resolution (CR) that would fund the federal government beyond September 30 includes nearly all of H.R.
  • In addition to funding for the Department of Homeland Security (DHS), the inclusion of key provisions of H.R.
  • 2 requires that DHS invest in physical barriers, personnel and technology to secure the border.
  • "Congress cannot hand the Biden administration a blank check that allows them to continue subverting our immigration laws and endangering national security.

NaaS Technology Inc. Joins NASDAQ Golden Dragon China Index, One of Nine Among New Energy Companies

Retrieved on: 
Monday, September 18, 2023
EV, NAAS, Q2, Network as a service, Tengzhou, Carbon, Index, PICC, US, Fortune 500, Hyundai, ECO, CR, Invesco, RMB, Lithium, Cryptocurrency

BEIJING, Sept. 18, 2023 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS), the first U.S. listed EV charging service company in China, today announced its inclusion in the NASDAQ Golden Dragon China Index, making it one of nine new energy companies and the only EV charging service company to be part of this index.

Key Points: 
  • BEIJING, Sept. 18, 2023 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS), the first U.S. listed EV charging service company in China, today announced its inclusion in the NASDAQ Golden Dragon China Index, making it one of nine new energy companies and the only EV charging service company to be part of this index.
  • The NASDAQ Golden Dragon China Index is widely recognized as a critical gauge for evaluating the performance of Chinese enterprises in the U.S. stock market.
  • It covers a diverse range of sectors, encompassing digital, technology, new forms of consumption, and clean energy, featuring renowned companies in the internet space and the new energy sector, among others.
  • NaaS' inclusion enriches the NASDAQ Golden Dragon China Index and brings fresh vigor to the new energy sector with its charging services.

NaaS Debuts at the 20th China-ASEAN Expo to Showcase Pioneer Services for Global Energy Market

Retrieved on: 
Sunday, September 17, 2023
EV, NAAS, Original equipment manufacturer, Network as a service, AC, SEK, USD, PICC, Hyundai, Kilowatt-hour, CR, Yoy, Ecosystem, TPES, Renewable energy, ASEAN

NaaS Technology Inc. (NASDAQ: NAAS), a leading EV charging service provider, is poised to make its premiere at the event, and are set to showcase their innovative products and energy digitalization solutions at the expo.

Key Points: 
  • NaaS Technology Inc. (NASDAQ: NAAS), a leading EV charging service provider, is poised to make its premiere at the event, and are set to showcase their innovative products and energy digitalization solutions at the expo.
  • In the process of energy transition, the new energy industry stands as the frontier of globalization-a theme that resonates worldwide.
  • The huge market potential has attracted heightened attention from an expanding array of global stakeholders, where NaaS seizes this opportunity well and makes prominent proceeds.
  • The partnerships will bring out collaboration in charging infrastructure construction as well as digital and intelligent application of new energy.

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Friday, September 15, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neutropenia, Civil service commission, American Journal of Clinical Oncology, HER2, Neoplasm, DCR, European Medicines Agency, Committee on Herbal Medicinal Products, International Association, Lung cancer, Mutation, ILD, Pneumonitis, ERBB2, NSCLC, Immunotherapy, Lung, AstraZeneca, Doctor of Philosophy, Committee, EMA, Journal, Dor, MD, Patient, European, Daiichi Sankyo, Anemia, CR, Committee for Medicinal Products for Human Use, ADC, R, Conference, ORR, European Commission, CHMP, Pharmaceutical industry, Fine chemical, Bachelor of Medicine, Bachelor of Surgery, EU

ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU.
  • “ENHERTU is the first therapy to demonstrate a strong and durable tumor response in patients with previously treated HER2 mutant advanced non-small cell lung cancer, validating HER2 as an actionable target in lung cancer and supporting the potential to provide a much-needed option for these patients,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.
  • Grade 3 or higher treatment-related treatment emergent adverse events (TEAEs) occurred in 38.6% of all patients receiving ENHERTU 5.4 mg/kg.

Canon Announces CR-N100 4K PTZ Camera and Flagship RC-IP1000 Remote Camera Controller

Retrieved on: 
Wednesday, September 13, 2023
Education, DIGIC, MCMA, USB, UVC, IP, HDMI, PTZ, Pan–tilt–zoom camera, USB video device class, CMOS, Workload, CR, Camera, Sport, Canon, Zoom

The camera is designed for indoor use-cases and brings the excellent image quality and performance that Canon PTZ cameras are known for at a lower price point.

Key Points: 
  • The camera is designed for indoor use-cases and brings the excellent image quality and performance that Canon PTZ cameras are known for at a lower price point.
  • Canon is also introducing the RC-IP1000, a high-end remote camera controller designed for professional systems.
  • As a free download, Canon will also release the Multi-Camera Management Application that streamlines the configuration and management of supported Canon PTZ, professional video, and cinema cameras.
  • The Canon RC-IP1000 Remote Camera Controller is scheduled to be available in mid-December, and the estimated retail price is still to be determined*.

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
Tuesday, September 12, 2023
Hodgkin lymphoma, Affimer, Non-Hodgkin lymphoma, Cancer, Fast Track, NK, Patient, Collection, HL, CR, FDA, IND, ORR, Safety, Pharmaceutical industry

The combination treatment is entering Phase 2 development and will be investigated in Affimed’s LuminICE-203 study ( NCT05883449 ), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.

Key Points: 
  • The combination treatment is entering Phase 2 development and will be investigated in Affimed’s LuminICE-203 study ( NCT05883449 ), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.
  • “Our clinical data of AFM13 in combination with allogeneic NK cells has shown outstanding efficacy and a well-managed safety profile in late-stage, muti-refractory, patients with r/r Hodgkin and Non-Hodgkin lymphoma,” said Dr. Wolfgang Fischer, Chief Operating Officer at Affimed.
  • The FDA’s decision is based on available data showing the potential of the AFM13 and AlloNK® combination therapy to overcome current limitations in the treatment of r/r HL.
  • With the Fast Track Designation, the therapeutic development of the combination can benefit from more frequent engagement with the FDA, which will support the collection of appropriate data needed to accelerate its development.

Host Hotels & Resorts Publishes 2023 Corporate Responsibility Report

Retrieved on: 
Monday, September 11, 2023
Workforce, Sustainability Accounting Standards Board, LEED, HST, Howard University, Arne, Woman, Host Hotels & Resorts, DEIB, TCFD, Equity, Independent Board for Presbyterian Foreign Missions, Task Force on Climate Related Financial Disclosures, Trust, Sustainability accounting, Report, Investment, Corporation, Host, CR, DEI, ESG, Environment, Corporate responsibility, Female, Renewable energy, Management

BETHESDA, Md., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, released its 2023 Corporate Responsibility (CR) Report, which details the Company’s CR program and responsible investment strategy along with its environmental, social and governance (ESG) initiatives, performance, progress and industry-leading accomplishments.

Key Points: 
  • BETHESDA, Md., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, released its 2023 Corporate Responsibility (CR) Report, which details the Company’s CR program and responsible investment strategy along with its environmental, social and governance (ESG) initiatives, performance, progress and industry-leading accomplishments.
  • Additionally, the 2023 CR Report introduces the next generation environmental and social performance targets for 2030 that will serve as an interim step to achieving the Company’s aspirational vision of becoming net positive by 2050.
  • “We are proud of our CR program accomplishments this past year as we continued to advance our social and employee-related initiatives and further solidified our position as an industry leader in environmental sustainability,” said Mike Lentz, executive vice president, development, design & construction and executive sponsor of the CR program.
  • “As we transform our 2025 environmental and social targets into business as usual, we are looking forward to focusing our ESG efforts and investments toward achieving our new 2030 goals and targets, which are centered around the most impactful areas of our business and reflect the broader reach and influence of our CR program.

NaaS Records 132% YoY Revenue Growth and 112% YoY Increase of Charging Volume reaching 2,251 GWh in H1 2023

Retrieved on: 
Friday, September 8, 2023
EV, NAAS, Network as a service, SEK, USD, PICC, US, Fortune 500, Hyundai, Kilowatt-hour, Invesco, CR, Ecosystem, RMB, Cryptocurrency, Renewable energy

Charging volume transacted through NaaS’ network reached 1,228 GWh in the second quarter of 2023 and 2,251 GWh in the first half of 2023, representing an increase of 112% and 112% year over year, respectively.

Key Points: 
  • Charging volume transacted through NaaS’ network reached 1,228 GWh in the second quarter of 2023 and 2,251 GWh in the first half of 2023, representing an increase of 112% and 112% year over year, respectively.
  • Non-IFRS net loss attributable to ordinary shareholders increased by 12% year over year to RMB108.0 million (US$14.9 million) in the second quarter of 2023.
  • Invesco WilderHill Clean Energy ETF, a subsidiary of global asset management magnate Invesco Ltd., has a large position of NaaS stock.
  • In the second quarter, 53.4% of NaaS' revenue goes to its offline and innovative services, achieving an unprecedented ratio of over 50%.

ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial

Retrieved on: 
Monday, September 11, 2023
Biotechnology, FDA, Health, Clinical Trials, Oncology, Neutropenia, Belfer Center for Science and International Affairs, Central nervous system, American Journal of Clinical Oncology, Progression-free survival, HER2, DCR, OS, Journal of Thoracic Oncology, International Association, Lung cancer, ILD, Pneumonitis, NSCLC, Lung, Doctor of Philosophy, AstraZeneca, PFS, Journal, Dor, MD, Patient, Daiichi Sankyo, Anemia, CR, ADC, CRS, Diagnosis, R, George M. Low Center for Industrial Innovation, Conference, ORR, Disease, Dana–Farber Cancer Institute, Medical imaging, Copper, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).

Key Points: 
  • Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).
  • Median OS was 19.5 months (95% CI: 13.6-NE) in the 5.4 mg/kg arm and not reached (95% CI: 12.1-NE) in the 6.4 mg/kg arm.
  • Baseline central nervous system metastases were present in 34.3% of patients in the 5.4 mg/kg arm and 44.0% of patients in the 6.4 mg/kg arm.
  • Median follow-up was 11.5 months (range 1.1-20.6) in the 5.4 mg/kg arm and 11.8 months (range 0.6-21.0) in the 6.4 mg/kg arm.

Canon Introduces CR-N100 PTZ Camera, Controller, and Cine Lens Line; More Info at B&H

Retrieved on: 
Tuesday, September 12, 2023
IR, Wi-Fi, NU, RCP, SRT, OSD, Blog, Power over Ethernet, IP, HDMI, PTZ, CMOS, CR, Camera, Explora, Canon

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- B&H is pleased to share the announcement of Canon, which include the CN-R Cinema RF-Mount Prime Lens line, the CR-N100 4K PTZ Remote Camera in either black or white, and the RC-IP1000 remote Camera Controller. The advanced cine primes feature native RF-mounts, full communication, 8K support, and they cover full-frame sensors to bring cinema-quality imagery to your kit. Rev up your remote-controlled camera setup with the CR-N100 cameras for your 4K production with 20x optical zoom, tally, and precise movements, and they can be controlled remotely by the sophisticated RC-IP1000 controller.  

Key Points: 
  • The CR-N100 sports resolutions up to 4K30 and can slip right into your 4K broadcast, reality show, event, or digital film production with ease.
  • The camera's lens features 20x optical zoom and optical image stabilization, and the CMOS sensor supports advanced hybrid autofocus to keep your images sharp from wide or telephoto perspectives.
  • It can also be used as a webcam for video conferencing and vlogging using its fast USB-C 3.0 output.
  • For more information about the new Canon PTZ camera, controller, and RF cine lens line, including additional features, specs, and highlights, be sure to check out the detailed product pages and Explora blog.